Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Halozyme Therapeutics (HALO) , which belongs to the Zacks Medical - Biomedical and Genetics industry.When looking at the last two reports, this biopharmaceutical company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 12.73%, on average, in the last two quarters.For the most recent quarter, Halozyme Therapeut ...